136 related articles for article (PubMed ID: 11118849)
1. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
2. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
[TBL] [Abstract][Full Text] [Related]
5. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
7. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
9. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
Portnoy YA; Vostrov SN; Lubenko IY; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
[TBL] [Abstract][Full Text] [Related]
10. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH
Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
[TBL] [Abstract][Full Text] [Related]
11. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
13. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model.
Firsov AA; Lubenko IY; Portnoy YA; Zinner SH; Vostrov SN
Antimicrob Agents Chemother; 2001 Mar; 45(3):927-31. PubMed ID: 11181382
[TBL] [Abstract][Full Text] [Related]
14. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
[TBL] [Abstract][Full Text] [Related]
15. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Zinner SH; Cornaglia G; Portnoy YA
Antimicrob Agents Chemother; 1998 Nov; 42(11):2848-52. PubMed ID: 9797214
[TBL] [Abstract][Full Text] [Related]
16. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
[TBL] [Abstract][Full Text] [Related]
17. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
[TBL] [Abstract][Full Text] [Related]
18. Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.
Braga PC; Dal SM; Woodnutt G
J Chemother; 2002 Feb; 14(1):41-6. PubMed ID: 11892898
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
[Next] [New Search]